Post Approval Observational Study to Learn More About How Safe Octocog Alfa is and How Well it Works in Patients With Severe Hemophilia A in India

Exclusion Criteria

• •Known contraindication according to the local prescriber information
• •Patients who are participating in an investigational program with interventions outside of routine clinical practice.
• •Patients with any other diagnosis of bleeding/coagulation disorder other than Hemophilia A.
• •Patients who are on ongoing prophylactic treatment with any FVIII concentrate or non-factor treatments like emicizumab.
• •Patients exhibiting any of the following laboratory abnormalities at screening:
• •Known platelet count \<100,000 mm3
• •Known Serum Creatinine \>2 folds upper the normal limit
• •Known Hepatic AST or ALT \>5 folds upper the normal limit
• •Patients who have received an on-demand infusion with any other FVIII (different to Octocog alfa), FVII or Activated prothrombin complex concentrate product (aPCC/FEIBA) 72 hours before the enrollment.
• •History or presence of FVIII inhibitor with a titer ≥ 0.6 with Nijmegen modified Bethesda Assay (NBA), or a clinical history suggestive of an inhibitor necessitating changes to treatment
• •Patient concerns or other barriers precluding adequate understanding or cooperation.